Table 4.
OVA1 Performance by Histological Subtype and FIGO Stage When Low-Risk CA125 *.
| OVA1 n/N | ||||||
|---|---|---|---|---|---|---|
| Histological Subtype | All | Stage I | Stage II | Stage III | Stage IV | Not Staged |
| Serous | 14/17 | 2/2 | 2/2 | 5/5 | 4/5 | 1/3 |
| Mucinous | 11/19 | 7/13 | 2/3 | 2/3 | ||
| Clear cell | 4/8 | 3/4 | 0/2 | 1/2 | ||
| Endometrioid | 1/3 | 1/2 | 0/1 | |||
| Carcinosarcoma | 2/2 | 1/1 | 1/1 | |||
| Carcinoid | 0/2 | 0/1 | 0/1 | |||
| Mixed | 1/1 | 1/1 | ||||
| Poorly differentiated | 1/1 | 1/1 | ||||
| Other epithelial cancer | 1/1 | 1/1 | ||||
| Germ cell | 1/1 | 1/1 | ||||
| Sex cord stromal | 5/8 | 3/5 | 1/1 | 1/2 | ||
| Granulosa cell tumor | 4/10 | 3/6 | 1/4 | |||
| Other non-epithelial cancer | 1/2 | 1/2 | ||||
* Low-risk CA125, 67 U/mL for premenopausal subjects; 35 U/mL for postmenopausal or unknown subjects.